A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept

Japanese Journal of Clinical Immunology

Volumn 35, Issue 5, 2012, Pages 433-438

  Wada, Takuma ^a   Akiyama, Yuji ^a   Yokota, Kazuhiro ^a   Sato, Kojiro ^a   Funakubo, Yu ^a   Mimura, Toshihide ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

abatacept; interstitial pneumonia; rheumatoid arthritis

Indexed keywords

EID: 85013000115     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.35.433     Document Type: Article

References (18)

1. Feldmann M., et al.: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol, 14: 397–440, 1996.
2. Vital E. M., Emery P.: Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag., 2(4): 365–375, 2006.
3. Genovese M. C., et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med, 353: 1114–1123, 2005.
4. Singh J. A., et al.: Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev., Feb 16 (2), 2011.
5. Yokota K., et al.: Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis. Rheumatol Int, 29: 459–461, 2009.
6. Golden M. R., et al.: The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol, 22: 1043–1047, 1995.
7. Wolfe F., et al.: Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol, 36: 172–178, 2007.
8. Dascalu C., et al.: Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol, 16: 172–174, 2010.
9. Huggett M. T., et al.: Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford), 45: 1312–1313, 2006.
10. Taki H., et al.: Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int, 30: 275–276, 2009.
11. Sakaida H., et al.: Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept. Mod Rheumatol, 20:611–616, 2010.
12. Yamazaki H., et al.: A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol, 20:518–521, 2010.
13. Roberto Perez-Alvarez, et al.: Interstitial lung disease induced or exacerbated by TNF-target-ed therapies: Analysis of 122 cases. Semin Arthritis Rheum., 41(2): 256–264, 2011.
14. Piguet P. F., Vesin C.: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J., 7(3): 515–518, 1994.
15. Miyazaki Y., et al.: Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveoitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest, 96(1): 250–259, 1995.
16. Vassallo R., et al.: Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest, 122: 1093–1096, 2002.
17. Dixon W. G., et al.: Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 69 (6): 1086–1091, 2010.
18. Hadjinicolaou A. V., et al.: Non-infectious pulmonary complications of newer biological agents for rheumatic disease-a systematic literature review. Rheumatology (Oxford), 50: 2297–2305, 2011.